# Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

> **NCT00367497** · PHASE2 · TERMINATED · sponsor: **Keio University** · enrollment: 5 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin

## Key facts

- **NCT ID:** NCT00367497
- **Lead sponsor:** Keio University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The stopping rule was applied because of low response rates.
- **Last updated:** 2007-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00367497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00367497, "Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00367497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*